Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Sulforadex in Healthy Volunteers SAD

This study has been completed.
Information provided by (Responsible Party):
Evgen Pharma Identifier:
First received: September 11, 2013
Last updated: September 18, 2013
Last verified: September 2013
To determine the safety and tolerability of single escalating doses of Sulforadex® in healthy male volunteers.

Condition Intervention Phase
Stage, Prostate Cancer
Drug: Sulforadex
Drug: Alpha cyclodextrin
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of Sulforadex® in Healthy Male Subjects

Resource links provided by NLM:

Further study details as provided by Evgen Pharma:

Primary Outcome Measures:
  • Safety [ Time Frame: 2 days ]
    Safety assessments will include standard laboratory safety tests (haematology, biochemistry, coagulation and urinalysis), vital signs, physical examinations, 12-lead ECG, telemetry and AE monitoring.

Enrollment: 29
Study Start Date: November 2012
Study Completion Date: February 2013
Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Sulforadex
Active compound
Drug: Sulforadex
Active compound
Other Name: Stabilised sulforaphane
Experimental: alpha Cyclodextrin
Placebo control arm
Drug: Alpha cyclodextrin
Placebo control

Detailed Description:

This study will be conducted in a randomised, double-blind, placebo-controlled design with single ascending doses of Sulforadex® administered to healthy male subjects between 18 to 45 years of age. Each healthy subject will receive verbal and written information followed by signing of the Informed Consent Form (ICF).

Subjects will be screened within 21 days prior to admission. At this visit a medical examination will be performed to assess eligibility of the healthy subject. Screening will be conducted over 1 day or may be divided into more than 1 day. The first cohort of the study will commence with one sentinel group. The subsequent groups may be dosed together without sentinel dosing. The study is expected to have 5 cohorts with a total of 29 healthy male subjects:


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy male subjects aged between 18 and 45 years (inclusive) at screening.
  2. Had a Body Mass Index (BMI) between 18.5 and 25.0 kg/m2 (inclusive) at screening.
  3. Subjects agreed to use acceptable methods of contraception

Exclusion Criteria:

  1. Subjects could not refrain from eating brassica vegetables or using brassica containing supplements for at least 7 days prior to the drug administration.
  2. History or clinical evidence of clinically significant disease or any condition or disease that affects drug absorption, distribution or excretion.
  3. Any history of clinically significant abnormal laboratory, vital signs or other safety findings as determined by medical history, physical examination or other evaluations conducted at screening or on admission.
  4. Electrocardiogram (ECG) abnormalities in the standard 12-lead ECG (at screening and Day -1) and 24-hour 5-lead Holter ECG (at screening) which in the opinion of the Investigator interfered with the ECG analysis.
  5. Any history or current evidence of clinically relevant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrinological, metabolic, neurological or psychiatric disease.
  6. Positive screen for Hepatitis B (Hepatitis B surface Antigen, HBsAG), Hepatitis C (Hepatitis C Antibody, anti-HCV) or HIV.
  7. Confirmed positive results from urine drug screen at screening and on admission (Day

    -1) indicating drug abuse including: amphetamines, benzodiazepines, cocaine, cannabinoids, opiates, barbiturates, tricyclic antidepressants and methadone or a confirmed positive alcohol breath test at screening and on admission (Day -1).

  8. History or clinical evidence of alcoholism or drug abuse. Alcohol abuse is defined as regular weekly intake of more than 14 units if female and 21 units if male (Using alcohol tracker; drug abuse is defined as compulsive, repetitive and/or chronic use of drugs or other substances with or without problems related to their use and/or where stopping or a reduction in dose will lead to withdrawal symptoms.
  9. Subject was mentally handicapped.
  10. Participation in another drug trial within 90 days prior to first drug administration.
  11. Use of any medication (including over-the-counter [OTC] medication) within 2 weeks prior to admission (Day 1) or within 10 times the elimination half-life of the respective drug or anticipated concomitant medication during the treatment periods. Limited amounts of paracetamol were allowed to treat AEs.
  12. Subjects who had donated more than 500 mL of blood within 90 days prior to drug administration.
  13. Smoking more than 10 cigarettes or equivalent amount of tobacco per day and subjects who could not stop smoking for the duration of the study whilst in the CPU.
  14. Treatment with herbal or sulforaphane containing supplements during the 7 days prior to dosing, or use of vitamins during 48 hours prior to admission (Day -1).
  15. Any circumstances or condition(s) that in the opinion of the Investigator would compromise full participation in the trial or compliance with the protocol.
  16. Subjects with legal incapacity or limited legal capacity at screening.
  17. Subjects who were vegetarians, vegans or have medical dietary restrictions.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01948362

United Kingdom
Richmond Pharmacology
London, United Kingdom, SW17 0RE
Sponsors and Collaborators
Evgen Pharma
Principal Investigator: Jörg Täube, MD FFPM Richmond Pharmacology
  More Information

Responsible Party: Evgen Pharma Identifier: NCT01948362     History of Changes
Other Study ID Numbers: EVG001N
Study First Received: September 11, 2013
Last Updated: September 18, 2013 processed this record on April 25, 2017